The curative effects and related analysis of bezafibrate combined medroxyprogesterone acetate in the treatment of AML
10.3969/j.issn.1671-8348.2014.06.010
- VernacularTitle:苯扎贝特联合醋酸甲羟孕酮治疗急性髓系白血病疗效观察分析
- Author:
Mingyue ZENG
;
Pengxiang GUO
;
Jishi WANG
- Publication Type:Journal Article
- Keywords:
leukemia,myeloid,acute;
bezafibrate;
medroxyprogesterone acetate
- From:
Chongqing Medicine
2014;(6):666-667,670
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the curative effects of bezafibrate combined medroxyprogesterone acetate in the treatment of AML .Methods 40 cases of AML patients were collected and devided into experimental group (bezafibrate combined medroxypro-gesterone acetate ,6 cases) ,control group (chemotherapy ,28 cases) and non-treatment group (6 cases) ,then through a prospective analysis we studied the curative effects and related results of bezafibrate combined medroxyprogesterone acetate in the treatment of AML .Results The median survival time of the experiment group (accepted bezafibrate combined medroxyprogesterone acetate ) was 15 weeks ;the median survival time of the control group (accepted chemotherapy ) was 24 weeks ;the median survival time of the giving up group(accepted any therapy ) was 8 weeks .Conclusion Bezafibrate combined medroxyprogesterone acetate could prolong the survival time of AML patients and there were no obvious adverse reactions .
